




U.S. Appln. No. 10/773,446 – INANA et al.
Title: Method and Compositions for
Treating Retinal Disease
Attorney Docket No. 39532-192229
1 of 15



PROBE 2

FIG. 1B

PROBE 1

FIG. 1A






FIG. 2A




PHASE

FIG. 2B




SR STAIN

FIG. 2C




BOUND ROS

FIG. 2D



INGESTED ROS

FIG. 2E



BPEI-1 CELLS SHOWING ROS BINDING (5-9 hr) AND INGESTION (11 -22 hr)

FIG. 3






FIG. 4



SEVERITY

+3 - +4


FIG. 5A



SEVERITY

+2 - +3

FIG. 5B



SEVERITY

0 - +1

FIG. 5C




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 7




FIG. 8A




FIG. 8B




FIG. 8C




FIG. 8D

FIG. 8E

FIG. 8F

FIG. 8G

FIG. 8H







FIG. 9



+ X-arrestin Ab
FIG. 10C



CONTROL
FIG. 10B



+MT1-MMP Ab
FIG. 10A






FIG. 11B





O.S. X-arrestin Ab
FIG. 11D



O.S. MT1-MMP Ab
FIG. 11A



O.D. UNINJECTED
FIG. 11C







FIG. 13

MT1-MMP Exon 5 PCR PRODUCT (SEQ ID NO: 59)

```
1   GGGAGGCTGA GGAAGGGAC TCAGGCTGCT ATCGTCACTG TCCCCATCCTT
51  CCAGGAAATG ACATCTTCCT GGTGGCTGTG CACGAGCTGG GCCATGCCCT
101 GGGGCTCGAG CATTCCAGTG ACCCCTCGGC CATCATGGCA CCTTTTTACC
                                     codon 259
151 AGTGGATGGA CACGGAGAAT TTTGTGCTGC CCGATGATGA CCGCCGGGGC
                                     codon 273
201 ATCCAGCAAC TTTATGGCGA GTAGTCTACA CCCACGCCTG CTCCCTCCTC
251 TGCTGCTTGT TCCCTCCTGG TCTACGCATT TCCCC
```

FIG. 14



1 MONTH AFTER INJECTION

FIG. 15A



UNINJECTED

FIG. 15B